Fluidic Hemostat Agent Using Silanol POSS Carrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hemostatic agents, both solid and liquid, are inadequate for effectively managing traumatic hemorrhages, especially in non-compressible areas and internal bleeding, as they lack sufficient viscoelastic properties to remain at the wound site and facilitate clot formation.
Innovation Solution
A fluidic hemostat agent comprising a solid hemostatic additive suspended in a silanol carrier fluid, such as polyhedral oligomeric silsesquioxanes, which provides both flowability for injection and viscoelastic characteristics to remain at the wound site, enabling the clotting cascade to form a thrombus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If liquid hemostats are used to provide topical hemostasis, then ease of use and rapid deployment are improved, but viscosity is too low to stop or significantly reduce the rate of blood loss from traumatic hemorrhage
Solution Approach 1:
The patent combines liquid hemostatic agents with solid particulate materials (such as chitosan, cellulose, kaolin, or silica particles) to create a composite hemostatic composition. This composite structure provides the liquidity and ease of application of liquid agents while the solid particles contribute to increased viscosity and mechanical hemostatic action, resolving the contradiction between ease of use and sufficient viscosity to control hemorrhage
2Reliability
If traditional solid hemostatic agents are used, then hemostatic activity is improved, but they cannot be applied to internal bleeding or difficult-to-access bleeding sites
Solution Approach 1:
The patent transforms solid hemostatic agents into a liquid or semi-liquid formulation by suspending particulate hemostatic materials in a liquid carrier. This parameter change in physical state allows the composition to be injected through catheters or syringes into internal bleeding sites while maintaining the hemostatic activity of the solid particles, thereby achieving both reliable hemostasis and adaptability to internal bleeding
3Reliability
If gauze-based devices are used to apply hemostatic agents, then hemostatic function is provided, but removal frequently causes dislodgement of thrombus and re-bleeding
Solution Approach 1:
The patent employs a liquid or injectable formulation that can be delivered hydraulically through syringes or catheters directly to the bleeding site. This liquid delivery method eliminates the need for gauze-based mechanical application and removal, allowing the hemostatic agent to remain in place as a liquid or gel that supports thrombus formation without causing re-bleeding upon removal, thus resolving the contradiction between providing hemostatic function and enabling safe removal
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fluidic hemostat agent effectively reduces blood loss and promotes hemostasis in both arterial and venous injuries, maintaining hemostasis without compression and allowing for easy removal, thus addressing the limitations of existing hemostatic agents.
Implementation Method 1
a fluidic hemostat agent comprising a solid hemostatic additive suspended in a silanol carrier fluid
Implementation Method 2
An improved fluidic hemostat having viscoelastic properties is needed for such applications
Data Source
AI summary
A fluidic hemostat agent comprising a solid hemostatic additive suspended in a silanol carrier fluid to form a heterogeneous mixture that exhibits sufficient flowability to allow for injection and proliferation, while simultaneously having sufficient adhesive and viscoelastic characteristics to remain at the application site and enable the clotting cascade time to form a thrombus. The silanol carrier fluid preferably comprises liquid silanol-bearing POSS molecules, while the solid hemostatic additive preferably is selected from the group consisting of kaolin, chitin, chitosan, cellulose, keratin pectin, acetylated glucosamine, dry fibrin, gelatin, and calcium salts. A preferred silanol species is iso-octylPOSS trisilanol having the molecular representation [(i-ocylSiO1.5)4(i-octyl(OH)SiO1.0)3]Σ7.